Landing Med aims to make early cancer detection technologies accessible to all. We provide affordable AI cytology and digital pathology products and services for pathologists, cytologists and governments. By integrating automation, digital, AI, and cloud computing technologies into Pap smear testing, our lab successfully screened 1 million cervical cytology cases in 50 days.
“Landing Med’s revolutionary end-to-end AI-powered cervical cancer screening model gives China hope to achieve the 2030 WHO cervical cancer elimination strategy. Countries with high demand for screening but limited cytopathology resources, such as low and middle-income countries, can consider AI-assisted solutions like Landing Med’s.”
“Landing Med’s DNA ploidy technology for oral cancer primary diagnosis is well proven and effective.”
“Landing Med is China’s benchmark for population-based cervical cancer screening.”
“The compact LD Patho 320A scanner is a good solution for pathology researchers"
“Landing Med’s revolutionary end-to-end AI-powered cervical cancer screening model gives China hope to achieve the 2030 WHO cervical cancer elimination strategy. Countries with high demand for screening but limited cytopathology resources, such as low and middle-income countries, can consider AI-assisted solutions like Landing Med’s.”
“Landing Med’s DNA ploidy technology for oral cancer primary diagnosis is well proven and effective.”
“Landing Med is China’s benchmark for population-based cervical cancer screening.”
“The compact LD Patho 320A scanner is a good solution for pathology researchers"
CN
